FIRST LINE THERAPY
Clinical trials for FIRST LINE THERAPY explained in plain language.
Never miss a new study
Get alerted when new FIRST LINE THERAPY trials appear
Sign up with your email to follow new studies for FIRST LINE THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug attack on Hard-to-Treat stomach cancer shows promise in early trial
Disease control Recruiting nowThis Phase II trial is testing a combination of three drugs—zanidatamab, pembrolizumab, and chemotherapy—in 80 people with advanced stomach or esophageal cancer that has spread and tests positive for HER2 and PD-L1. The goal is to see if this triple therapy can keep the cancer fr…
Matched conditions: FIRST LINE THERAPY
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Promising new combo aims to improve remission in Tough-to-Treat leukemia
Disease control Recruiting nowThis study compares a new treatment (venetoclax plus CACAG) to the standard chemotherapy for adults newly diagnosed with intermediate- or high-risk acute myeloid leukemia (AML). About 160 participants aged 14 to 75 will be randomly assigned to one of the two groups. The main goal…
Matched conditions: FIRST LINE THERAPY
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New cocktail targets Hard-to-Treat stomach cancer
Disease control Recruiting nowThis study tests a combination of three drugs (fruquintinib, trastuzumab, and chemotherapy) as a first treatment for people with HER2-positive advanced stomach or gastroesophageal junction cancer. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth…
Matched conditions: FIRST LINE THERAPY
Phase: PHASE1, PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC